#75 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
“Until we have FDA-approved cannabis medicines with standardized dosing and demonstrated efficacy in rigorous trials, we’re asking patients to become their own pharmacologists, adjusting dosages and products based on trial and error rather than evidence, which is fundamentally at odds with how we practice medicine in every other domain.”
💊 The evolving regulatory landscape for cannabis-derived medicines reflects growing recognition that some cannabinoid compounds warrant clinical evaluation through conventional pharmaceutical pathways, though the summary provided contains insufficient detail to assess specific claims about FDA approvals or ongoing regulatory proceedings. Clinicians should remain cautious about distinguishing between FDA-approved cannabis-derived pharmaceuticals (currently limited to cannabidiol for specific seizure disorders and synthetic cannabinoids like dronabinol), which have established dosing and safety profiles, and medical cannabis products that remain largely unregulated and poorly characterized in terms of potency, purity, and drug interactions. The current gap between emerging basic science suggesting potential therapeutic applications and the rigorous clinical trial data needed to inform practice means that clinicians recommending or discussing cannabis with patients should acknowledge this uncertainty explicitly and document discussions about lack of evidence for most proposed uses. Regulatory appeals and industry advocacy may eventually expand the evidence base for specific cannabinoid formulations,
💬 Join the Conversation
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
